KITE : Insider Transactions for Kite Pharma, Inc. | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Kite Pharma, Inc. (KITE)

$0.00 0.00 (0.00%) as of 4:30 Fri 2/14

Download

Exchange:

N/A

Security Type:

N/A

Shares Out:

573,600,000

Market Cap:

N/A

Last Volume:

0

Avg Vol:

0

52 Week Range:

$179.79 - $179.79

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year


Company Profile

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	0	0
Total Buy Value	$0	$0	$0	$0
Total People Bought	0	0	0	0
Total Buy Transactions	0	0	0	0
Total Shares Sold	0	0	0	0
Total Sell Value	$0	$0	$0	$0
Total People Sold	0	0	0	0
Total Sell Transactions	0	0	0	0
End Date	2024-02-15	2023-11-14	2023-05-16	2022-05-16

Adjust Filter Settings

Records found: 387

Page 14 of 16

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Wiezorek Jeffrey

VP Clinical Development

• – –

2015-08-17

4

OE

$6.89

$62,010

D/D

9,000

14,218

-

Sproule Rizwana F

VP Regulatory Affairs

• – –

2015-08-17

4

AS

$60.21

$582,407

D/D

(9,567)

1,695

-

Sproule Rizwana F

VP Regulatory Affairs

• – –

2015-08-17

4

OE

$1.35

$12,915

D/D

9,567

11,262

-

Roberts Margo R

Chief Scientific Officer

• – –

2015-08-17

4

AS

$60.15

$374,236

D/D

(6,145)

999

-

Roberts Margo R

Chief Scientific Officer

• – –

2015-08-17

4

OE

$0.70

$14,815

D/D

6,145

7,144

-

VP, Product Sciences

• – –

2015-08-03

4

AS

$71.19

$649,246

D/D

(9,000)

1,017

-

VP, Product Sciences

• – –

2015-08-03

4

OE

$0.38

$3,420

D/D

9,000

10,017

-

EVP, R&D, Chief Medical Off.

• – –

2015-08-03

4

AS

$71.15

$555,242

D/D

(7,700)

6,000

-

EVP, R&D, Chief Medical Off.

• – –

2015-08-03

4

OE

$6.89

$53,053

D/D

7,700

13,700

-

Butitta Cynthia M

COO and CFO

• – –

2015-07-27

4

AS

$68.13

$684,818

D/D

(10,000)

74,566

-

Butitta Cynthia M

COO and CFO

• – –

2015-07-27

4

OE

$1.35

$13,500

D/D

10,000

84,566

-

Roberts Margo R

Chief Scientific Officer

• – –

2015-07-15

4

AS

$70.34

$1,593,674

D/D

(22,167)

999

-

Roberts Margo R

Chief Scientific Officer

• – –

2015-07-15

4

OE

$0.70

$236,252

D/D

22,167

23,166

-

Sproule Rizwana F

VP Regulatory Affairs

• – –

2015-07-15

4

AS

$70.54

$687,828

D/D

(9,567)

1,695

-

Sproule Rizwana F

VP Regulatory Affairs

• – –

2015-07-15

4

OE

$1.35

$12,915

D/D

9,567

11,262

-

Wiezorek Jeffrey

VP Clinical Development

• – –

2015-07-15

4

AS

$70.12

$647,257

D/D

(9,000)

5,218

-

Wiezorek Jeffrey

VP Clinical Development

• – –

2015-07-15

4

OE

$6.89

$62,010

D/D

9,000

14,218

-

EVP, R&D, Chief Medical Off.

• – –

2015-07-01

4

AS

$61.15

$476,781

D/D

(7,700)

6,000

-

EVP, R&D, Chief Medical Off.

• – –

2015-07-01

4

OE

$6.89

$53,053

D/D

7,700

13,700

-

VP, Product Sciences

• – –

2015-07-01

4

AS

$61.04

$557,075

D/D

(9,000)

1,017

-

VP, Product Sciences

• – –

2015-07-01

4

OE

$0.38

$3,420

D/D

9,000

10,017

-

Director

– • –

2015-06-30

4

S

$61.22

$41,403,803

I/I

(664,102)

1,761,957

-

Butitta Cynthia M

COO and CFO

• – –

2015-06-29

4

AS

$58.87

$596,542

D/D

(10,000)

74,566

-

Butitta Cynthia M

COO and CFO

• – –

2015-06-29

4

OE

$1.35

$13,500

D/D

10,000

84,566

-

Wiezorek Jeffrey

VP Clinical Development

• – –

2015-06-15

4

AS

$55.93

$513,031

D/D

(9,000)

5,218

-

387 Records found	Previous 10 11 12 13 14 15 16	Page 14 of 16

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.